Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus rhamnosus GG + Lactobacillus rhamnosus LC705 + Bifidobacterium breve Bb99 + Propionibacterium freudenreichii + galacto-oligosaccharides
- Development stage
- Unknown
- Lead developer
- University of Helsinki
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This synbiotic intervention, developed by the **University of Helsinki**, consists of a specific mixture of four probiotic bacterial strains—*Lactobacillus rhamnosus* GG, *Lactobacillus rhamnosus* LC705, *Bifidobacterium breve* Bb99, and *Propionibacterium freudenreichii* ssp. *shermanii* JS—combined with prebiotic galacto-oligosaccharides (GOS). The formulation is designed to modulate the neonatal gut microbiota and promote immune system maturation to prevent the development of allergic diseases. It is typically administered to pregnant women during the final weeks of gestation and subsequently to their infants for the first six months of life. Clinical research, including a Phase 2/3 trial conducted at the Skin and Allergy Hospital of Helsinki University, has demonstrated that this synbiotic approach significantly reduces the cumulative incidence of eczema and IgE-associated eczema in high-risk children, representing a microbiome-modulating strategy for allergy prevention.
- Other names
- Helsinki probiotic mixtureSynbiotic mixture (LGG, LC705, Bb99, PJS + GOS)
02
Targets
MUC2 (Mucin-2)
Beyond the preview
Go deeper on Lactobacillus rhamnosus GG + Lactobacillus rhamnosus LC705 + Bifidobacterium breve Bb99 + Propionibacterium freudenreichii + galacto-oligosaccharides.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus rhamnosus GG + Lactobacillus rhamnosus LC705 + Bifidobacterium breve Bb99 + Propionibacterium freudenreichii + galacto-oligosaccharides.